Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting

Lunit, a leading medical AI startup that develops AI-powered diagnostic and therapeutic imaging biomarkers, today announced that two abstracts showcasing findings from its AI pathology research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019. The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

The accepted abstracts feature results derived from AI analysis of diverse cancer types and also demonstrate how AI-powered identification/quantification of cancer tissue based on H&E-stained histology images, can be a potential prognostic & predictive biomarker for breast cancer. In one of the abstracts, high-risk patients, classified by Lunit’s AI, were around 5-times more likely to die than low-risk patients, based on overall survival. More remarkably, high-risk patients were 3 to 5-fold more likely to respond to adjuvant chemotherapy, based on disease-free survival and overall survival, respectively. These abstracts will be presented during AACR poster sessions on Monday and Tuesday, 1-2 April.

“In our journey of developing predictive biomarkers for lung and breast cancer, these abstracts mark the successful completion of the first phase of our research,” said Brandon Suh, CEO of Lunit. “Our research marks a meaningful milestone in cancer research aided by artificial intelligence. We look forward to accelerating our research and development in AI analysis of cancer tissues through various research partnerships.”

Lunit’s AI research in the field of pathology has been recognized to be world-leading in various occasions, ranked world #1 in both MICCAI TUPAC Challenge 2016 and CAMELYON 2017, ahead of competition like Microsoft and IBM.

Story image


According to Lunit, the company had employed an AI software, Lunit SCOPE, a deep learning-based H&E image analyzing tool that had been vital in the AI analysis of cancer tissues and the study itself. Lunit SCOPE will be available for demonstration during AACR, at Lunit booth #1744. An online demonstration is available at (Runs on Chrome Web Browser only)

“One of the most impressive results from our study is that an AI analysis of H&E stained slide images showed great potential in the prediction of response to adjuvant chemotherapy in breast cancer,” said Kyunghyun Paeng, Head of Precision Pathology at Lunit. “We are particularly excited about this finding, as it signals the beginning of our second phase of research, moving closer to developing predictive biomarkers in lung and breast cancer. We welcome research partners to join forces with us in this development.”  



Jussarang Lee Communications Manager
About Lunit

Perfecting Intelligence, Transforming Medicine.

With AI, we aim to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide.

We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.

Lunit, abbreviated from “learning unit,” is an AI software company devoted to developing advanced medical image analytics and data-driven imaging biomarkers via cutting-edge deep learning technology.

Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images. Lunit has been named by CB Insights as one of “AI 100” startups transforming healthcare industry.

Lunit's technology has been recognized at international competitions such as ImageNet (5th place, 2015), TUPAC 2016 (1st place), and Camelyon 2017 (1st place), surpassing top companies like Google, IBM, and Microsoft. Lunit is based in Seoul, South Korea.

15th floor, 27 Teheran-ro 2-gil, Gangnam-gu,
Seoul, South Korea